Werewolf Therapeutics (HOWL) News Today $0.70 -0.09 (-11.90%) Closing price 04:00 PM EasternExtended Trading$0.73 +0.03 (+4.97%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comWerewolf Therapeutics (HOWL) Gets a Buy from Bank of America SecuritiesMarch 28, 2025 | markets.businessinsider.comWedbush Research Analysts Cut Earnings Estimates for HOWLWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of Werewolf Therapeutics in a report released on Wednesday, March 12th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($1.84) per shaMarch 17, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for HOWL EarningsWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2025 earnings estimates for Werewolf Therapeutics in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now expects that the companyMarch 17, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)March 13, 2025 | markets.businessinsider.comWerewolf Therapeutics' (HOWL) Outperform Rating Reiterated at WedbushWedbush restated an "outperform" rating and set a $8.00 target price on shares of Werewolf Therapeutics in a report on Wednesday.March 13, 2025 | marketbeat.comWerewolf Therapeutics' (HOWL) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPSWerewolf Therapeutics (NASDAQ:HOWL - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.March 12, 2025 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPSWerewolf Therapeutics (NASDAQ:HOWL - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.March 12, 2025 | marketbeat.comWerewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with ChinaMarch 12, 2025 | tipranks.comWerewolf Therapeutics Reports 2024 Financial Results and ProgressMarch 12, 2025 | tipranks.comWerewolf Therapeutics reports Q4 EPS (46c), consensus (31c)March 11, 2025 | markets.businessinsider.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 11, 2025 | globenewswire.comWerewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma ConferenceMarch 4, 2025 | globenewswire.comWerewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on ThursdayWerewolf Therapeutics (NASDAQ:HOWL) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comWerewolf Therapeutics appoints Anil Singhal to board of directorsFebruary 24, 2025 | markets.businessinsider.comWerewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of DirectorsFebruary 24, 2025 | globenewswire.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Rises By 13.2%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 31st total of 1,520,000 shares. Approximately 5.2% of the company's stock are short sold. Based on an average daily trading volume, of 773,000 shares, the days-to-cover ratio is presently 2.2 days.February 3, 2025 | marketbeat.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in DecemberWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 15th total of 1,520,000 shares. Based on an average daily trading volume, of 773,000 shares, the days-to-cover ratio is currently 2.2 days. Currently, 5.2% of the company's shares are short sold.January 18, 2025 | marketbeat.comWerewolf Therapeutics price target lowered to $4 from $12 at JMP SecuritiesJanuary 14, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)January 14, 2025 | markets.businessinsider.comWerewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP SecuritiesJMP Securities cut their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating for the company in a research report on Tuesday.January 14, 2025 | marketbeat.comWerewolf Therapeutics provides business update, highlights 2025 outlookJanuary 14, 2025 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial PositionJanuary 14, 2025 | markets.businessinsider.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookJanuary 13, 2025 | finanznachrichten.deWerewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookJanuary 13, 2025 | globenewswire.comBank of America Securities Sticks to Their Buy Rating for Werewolf Therapeutics (HOWL)January 7, 2025 | markets.businessinsider.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Expands By 23.6%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,520,000 shares, an increase of 23.6% from the November 30th total of 1,230,000 shares. Based on an average daily trading volume, of 744,600 shares, the short-interest ratio is currently 2.0 days. Approximately 4.6% of the company's stock are sold short.December 31, 2024 | marketbeat.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,230,000 shares, a decline of 6.1% from the November 15th total of 1,310,000 shares. Based on an average trading volume of 712,600 shares, the short-interest ratio is currently 1.7 days. Approximately 3.8% of the shares of the stock are short sold.December 17, 2024 | marketbeat.comWerewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNovember 20, 2024 | globenewswire.comInnovative Cytokine Immunotherapy: Werewolf Therapeutics’ Pioneering Approach and Promising PipelineNovember 19, 2024 | markets.businessinsider.comWerewolf Therapeutics' (HOWL) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comFY2024 Earnings Estimate for HOWL Issued By Leerink PartnrsWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Werewolf Therapeutics in a report issued on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now forecasts that the comNovember 13, 2024 | marketbeat.comPromising Potential of Werewolf Therapeutics’ INDUKINE Platform Despite ChallengesNovember 13, 2024 | markets.businessinsider.comWerewolf Therapeutics Advances Innovative Cytokine TherapiesNovember 13, 2024 | markets.businessinsider.comBuy Rating for Werewolf Therapeutics: Strong Financial Position and Promising PipelineNovember 11, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for HOWL Q1 Earnings?Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Werewolf Therapeutics in a research report issued to clients and investors on Friday, November 8th. HC Wainwright analyst A. MaldonadoNovember 11, 2024 | marketbeat.comBuy Recommendation for Werewolf Therapeutics: Promising Developments in WTX-330 Clinical TrialsNovember 9, 2024 | markets.businessinsider.comWerewolf Therapeutics sees cash runway through 2Q26November 8, 2024 | markets.businessinsider.comWerewolf Therapeutics presents preclinical, clinical data on WTX-330November 8, 2024 | markets.businessinsider.comWerewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | markets.businessinsider.comWerewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingNovember 7, 2024 | globenewswire.comDark Wolf Nebula shows off a howling good view in awesome Halloween image (video)October 31, 2024 | msn.comLeonardo DiCaprio and Jane Goodall-Produced Movie ‘Howl’ Boarded by Pulsar Content, XYZ Films Ahead of AFM (EXCLUSIVE)October 31, 2024 | msn.comWerewolf Therapeutics announces addition of WTX-921 to pipelineOctober 31, 2024 | msn.comLeigh Whannell's Wolf Man Deviated From The Original Ryan Gosling Pitch, And The Writer/Director Told Me WhyOctober 22, 2024 | msn.comBank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ StocksOctober 19, 2024 | msn.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest UpdateWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant decline in short interest in September. As of September 30th, there was short interest totalling 1,040,000 shares, a decline of 7.1% from the September 15th total of 1,120,000 shares. Currently, 3.4% of the company's stock are short sold. Based on an average daily volume of 184,400 shares, the days-to-cover ratio is currently 5.6 days.October 16, 2024 | marketbeat.comMillennium Management LLC Raises Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)Millennium Management LLC increased its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 96.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,110,298 shares of the company's stock after purchasing an adOctober 16, 2024 | marketbeat.comWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 5, 2024 | finance.yahoo.com Remove Ads Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address HOWL Media Mentions By Week HOWL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOWL News Sentiment▼0.000.61▲Average Medical News Sentiment HOWL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOWL Articles This Week▼21▲HOWL Articles Average Week Remove Ads Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genfit News Nanobiotix News MediWound News Molecular Partners News Aclaris Therapeutics News Korro Bio News DiaMedica Therapeutics News Neumora Therapeutics News RAPT Therapeutics News Aardvark Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOWL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOWL Stock Free HOWL Stock Alerts